SCHEMBL2289678

SCHEMBL2289678

Cc1cccc(C)c1Nc1c(-c2ccccc2OCC(N)=O)nc2c(C)cccn12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 13/20 0.54
MAPT P10636 10/20 0.54
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
PDE5A O76074 1/20 0.42
ADORA1 P30542 1/20 0.40
TP53 P04637 5/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292004 0.93 GAA (0.46) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2288504 0.88 GAA (0.54) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2810374 0.87 GAA (0.66) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2287284 0.83 KCNN4 (0.39) GAAMAPTSMN1; SMN2LMNAADORA1
SCHEMBL2295279 0.83 GAA (0.48) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2287261 0.83 MAPT (0.45) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2290892 0.82 GAA (0.49) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2287174 0.82 GAA (0.44) GAAMAPTSMN1; SMN2HTTADORA1
SCHEMBL2292757 0.81 GAA (0.46) GAAMAPTTDP1SMN1; SMN2HTT
SCHEMBL2292520 0.81 GAA (0.45) GAAMAPTTDP1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885TDP1 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.